Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Market Cap	$1.16B	P/E Ratio	N/A
52W High	$10.08	52W Low	$3.14
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-45.6%	52W Position	58.1%
Overall Score	39	Value Score	20
Quality Score	63	Technical Score	36

EPS Current Est	$-0.03	EPS Next Est	$0.23
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XERS	$7.17	+2.28%	1.68M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XERS	$7.17	+2.3%	1.68M
3
4
5
6

XERS

XERS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Xeris Biopharma Holdings Inc. Data in Excel

Get Xeris Biopharma Holdings Inc. Data in Excel